BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Hyku Biosciences, a pioneer in precision medicine, today announced the appointment of Keith Wilcoxen, PhD, as Chief Scientific Officer. Dr. Wilcoxen has more than 25 years of experience advancing new therapies through preclinical and early clinical development..

马萨诸塞州伯灵顿，2025年3月19日（环球新闻社）——精准医学领域的先驱Hyku生物科学公司今天宣布任命Keith Wilcoxen博士为首席科学官。Wilcoxen博士在通过临床前和早期临床开发推进新疗法方面拥有超过25年的经验。

'We are thrilled to welcome Keith as our new Chief Scientific Officer,” said Kleem Chaudhary, PhD, President and CEO of Hyku Biosciences. “With deep expertise in chemistry, and a proven track record in early clinical development, he is the ideal leader to drive our scientific strategy forward. His insights and experience will be invaluable as we continue advancing our platform and pipeline toward transformative treatments for patients.”.

“我们非常高兴欢迎Keith担任我们的新任首席科学官，”Hyku Biosciences公司总裁兼首席执行官Kleem Chaudhary博士说道，“他在化学领域拥有深厚的专业知识，并在早期临床开发方面有着卓越的业绩记录，是推动我们科学战略前进的理想领导者。随着我们继续推进平台和产品管线，为患者带来变革性治疗，他的见解和经验将无比宝贵。”

Dr. Wilcoxen brings to Hyku a strong history of accomplishments in the biopharmaceutical industry. Most recently he served as Chief Development officer at Rome Therapeutics, where he led the advancement of the company’s pipeline programs. Prior to that, he was Senior Vice President of Global Research at Zenas BioPharma,and he held leadership roles at Boston Pharmaceuticals as Vice President of Diligence and Non-Clinical Development, and later as Vice President of Translational Research.

威尔科克斯博士为Hyku带来了生物制药行业丰富的成就历史。他最近担任Rome Therapeutics的首席开发官，领导了公司管线项目的推进。在此之前，他曾任Zenas BioPharma全球研究高级副总裁，并在Boston Pharmaceuticals担任过尽职调查和非临床开发副总裁以及转化研究副总裁等领导职务。

Earlier in his career, he held roles of increasing responsibility with Tesaro, Eisai, Neurocrine Biosciences, and Pfizer. Dr. Wilcoxen holds a Ph.D. in chemistry from Scripps Research Institute and a B.A. in chemistry from Northwestern University. Dr Wilcoxen has been a key contributor for the development of TSR-011, cobolimab, Jemperli™ (dostarlimab), Varubi™ (rolapitant) and Zejula™ (niraparib)..

在其职业生涯早期，他曾任职于Tesaro、Eisai、Neurocrine Biosciences和Pfizer，担任过责任日益增加的职位。Wilcoxen博士拥有Scripps研究所化学博士学位和西北大学化学学士学位。Wilcoxen博士在TSR-011、cobolimab、Jemperli™（dostarlimab）、Varubi™（rolapitant）和Zejula™（niraparib）的开发中发挥了关键作用。

“I am very excited to join Hyku and to be part of the company’s strong momentum and innovative drug discovery that expands the possibilities of discovery and development of new drug candidates,” said Dr. Wilcoxen.

“我非常激动能够加入Hyku公司，并成为公司强劲发展势头和创新药物发现的一部分，这扩大了新药候选物发现与开发的可能性，”威尔科森博士说道。

About Hyku Biosciences

关于Hyku生物科学

Hyku is a biotechnology company based in the greater Boston area, utilizing its proprietary discovery platform to inhibit disease targets that are challenging to address with conventional approaches. Hyku’s drug discovery engine is based on its proprietary platform technologies, which identify histidine, tyrosine and lysine-based binding pockets and enable rational drug design for the development of covalent or non-covalent medicines.

Hyku是一家位于大波士顿地区的生物技术公司，利用其专有的发现平台来抑制那些用传统方法难以解决的疾病靶点。Hyku的药物发现引擎基于其专有的平台技术，这些技术能够识别组氨酸、酪氨酸和赖氨酸结合口袋，并助力合理药物设计，以开发共价或非共价药物。

The platform pioneered by Hyku has the potential to fundamentally expand the scope of small molecule drug discovery, greatly increase the potential to modulate many target classes, and bring significant therapeutic benefits to patients via first-in-class and best-in-class medicines..

Hyku开创的平台有可能从根本上扩大小分子药物发现的范围，极大地增加调控许多靶点类别的潜力，并通过首创和最佳药物为患者带来显著的治疗益处。

To learn more, please visit

要了解更多信息，请访问

www.hykubiosciences.com

www.hykubiosciences.com

Contact:

联系人：

ir@hykubio.com

投资者关系@海裕生物.com